Inhibitory effect of schisandrin on migration and invasion of pancreatic cancer cells and its mechanism

Lu YANG, Jiacai FU, Fengjin LI, Ling QI

PDF(1335 KB)
PDF(1335 KB)
J Jilin Univ Med Ed ›› 2025, Vol. 51 ›› Issue (1) : 44-50. DOI: 10.13481/j.1671-587X.20250106
Research in basic medicine

Inhibitory effect of schisandrin on migration and invasion of pancreatic cancer cells and its mechanism

Author information +
History +

Abstract

Objective To discuss the inhibitory effect of schisandrin B (SchB) on the migration and invasion of the pancreatic cancer Pan02 cells, and to clarify its mechanism. Methods The pancreatic cancer Pan02 cells were treated with different concentrations of SchB (0, 0.78, 1.56, 3.12, 6.25, 12.50, and 25.00 mg·L-1) for 24, 48, and 72 h. CCK-8 method was used to detect the survival rates of the cells in various groups, and the concentration of SchB for the subsequent experiments was confirmed. The Pan02 cells were divided into control group, 2.5 mg·L-1 SchB group, 5.0 mg·L-1 SchB group, and 10.0 mg·L-1 SchB group. Wound healing assay was used to detect the wound healing rates of the Pan02 cells in various groups; Transwell chamber assay was used to detect the numbers of migration and invasion Pan02 cells in various groups; Western blotting method was used to detect the expression levels of Vimentin and N-cadherin proteins in the Pan02 cells in various groups.The mouse models of subcutameous transplanted tumor of pancreatic cancer cells were established.Ten successfully modeling mice were randomly divided into control group and SchB group (n=5). After 28 d of treatment, the weights of tumor of the mice were determined; immunohistochemistry method was used to detect the expressions of Vimentin and N-cadherin proteins in tumor tissue of the mice in various groups. Results The CCK-8 results showed that compared with control group, the survival rates of the pancreatic cancer Pan02 cells in different concentrations of SchB groups were decreased (P<0.05 or P<0.01). The wound healing results showed that compared with control group, the wound healing rates of the cells in 2.5, 5.0, and 10.0 mg·L-1 SchB groups were decreased (P<0.05 or P<0.01). The Transwell chamber results showed that compared with control group, the numbers of migration and invasion Pan02 cells in 2.5, 5.0, and 10.0 mg·L-1 SchB groups were decreased (P<0.05 or P<0.01). The Western blotting results showed that compared with control group, the expression levels of Vimentin and N-cadherin proteins in the Pan02 cells in 2.5, 5.0, and 10.0 mg·L-1 SchB groups were decreased (P<0.05 or P<0.01). Compared with control group, the tumor volume and weight of the mice in SchB group were significantly decreased(P<0.01). The immunohistochemistry results showed that compared with control group, the positive expression rates of Vimentin and N-cadherin proteins in tumor tissue of the mice in SchB group were significantly decreased (P<0.01). Conclusion SchB can inhibit the proliferation, migration, and invasion of the pancreatic cancer Pan02 cells, and its mechanism is related to the reduction of expressions of Vimentin and N-cadherin proteins.

Key words

Schisandrin B / Pancreas neoplasms / Cell migration / Cell invasion / N-cadherin / Vimentin

Cite this article

Download Citations
Lu YANG , Jiacai FU , Fengjin LI , et al. Inhibitory effect of schisandrin on migration and invasion of pancreatic cancer cells and its mechanism. Journal of Jilin University(Medicine Edition). 2025, 51(1): 44-50 https://doi.org/10.13481/j.1671-587X.20250106

References

1
PARK W CHAWLA A O’REILLY E M. Pancreatic cancer: a review[J]. JAMA2021326(9): 851-862.
2
STOFFEL E M BRAND R E GOGGINS M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention[J]. Gastroenterology2023164(5): 752-765.
3
SCHIZAS D CHARALAMPAKIS N KOLE C, et al. Immunotherapy for pancreatic cancer: a 2020 update[J]. Cancer Treat Rev202086: 102016.
4
马骏池, 赵晋彤, 高世勇, 等. 五味子乙素提纯工艺及药理作用研究进展[J]. 中国现代中药202224(3): 533-541.
5
LUO W LIN K HUA J Y, et al. Schisandrin B attenuates diabetic cardiomyopathy by targeting MyD88 and inhibiting MyD88-dependent inflammation[J]. Adv Sci20229(31): e2202590.
6
ZHANG Q LIU J DUAN H, et al. Activation of Nrf2/HO-1 signaling: an important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress[J]. J Adv Res202134: 43-63.
7
LI Z M ZHAO L J XIA Y S, et al. Schisandrin B attenuates hepatic stellate cell activation and promotes apoptosis to protect against liver fibrosis[J]. Molecules202126(22): 6882.
8
XU C H DENG Y MAN J W, et al. Unveiling the renoprotective mechanisms of schisandrin B in ischemia-reperfusion injury through transcriptomic and pharmacological analysis[J]. Drug Des Devel Ther202418: 4241-4256.
9
傅家财, 秦玲莎, 杨露, 等. 五味子乙素对胰腺癌Pan02细胞增殖的抑制作用及其机制[J]. 吉林大学学报(医学版)202450(3): 638-646.
10
向玲宝, 朱奕, 左玲, 等. 五味子乙素通过Wnt/β-catenin信号通路抑制膀胱癌增殖、迁移和侵袭[J].海南医学院学报202329(8): 568-574, 580.
11
王吉维, 郝文伟, 李盛涛, 等. 五味子乙素通过Wnt/β-catenin信号通路调节人胰腺癌细胞增殖、凋亡和侵袭[J]. 解剖科学进展202127(1): 58-60.
12
吴赛男. 五味子乙素对人宫颈癌Siha细胞增殖和迁移的影响及机制研究[D]. 吉林: 北华大学, 2021.
13
ACHARI A CHATTERJEE S DEY S, et al. Catecholase-catalyzed synthesis of wedelolactone, a natural coumestan and its analogs[J]. Org Biomol Chem202221(1): 89-92.
14
RODRÍGUEZ GIL Y JIMÉNEZ SÁNCHEZ P MUÑOZ VELASCO R, et al. Molecular alterations in pancreatic cancer: transfer to the clinic[J]. Int J Mol Sci202122(4): 2077.
15
KLEIN A P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors[J]. Nat Rev Gastroenterol Hepatol202118(7): 493-502.
16
徐彪铭, 左朝晖. 外泌体作为药物载体在胰腺癌化学治疗中的作用[J]. 中南大学学报(医学版)202348(2):268-274.
17
SKARKOVA V VITOVCOVA B MATOUSKOVA P, et al. Role of N-cadherin in epithelial-to-mesenchymal transition and chemosensitivity of colon carcinoma cells[J]. Cancers202214(20): 5146.
18
LOH C Y CHAI J Y TANG T F, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges[J]. Cells20198(10): 1118.
19
CAO Z Q WANG Z LENG P. Aberrant N-cadherin expression in cancer[J]. Biomed Pharmacother2019118: 109320.
20
BLASCHUK O W. N-cadherin antagonists as oncology therapeutics[J]. Philos Trans R Soc Lond B Biol Sci2015370(1661): 20140039.
21
SU Y LI J SHI C, et al. N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN[J]. Oncogene201635(25): 3335-3341.
22
ZHANG H WU X S XIAO Y Z, et al. Coexpression of FOXK1 and vimentin promotes EMT, migration, and invasion in gastric cancer cells[J]. J Mol Med201997(2): 163-176.
23
SATELLI A LI S L. Vimentin in cancer and its potential as a molecular target for cancer therapy[J]. Cell Mol Life Sci201168(18): 3033-3046.
24
PARVANIAN S COELHO-RATO L S PATTESON A E, et al. Vimentin takes a hike-Emerging roles of extracellular vimentin in cancer and wound healing[J]. Curr Opin Cell Biol202385: 102246.

杨露参与实验设计、实验操作、数据收集、数据分析、统计学分析和论文撰写,傅家财参与实验操作、数据收集、数据分析和统计学分析,李凤金和齐玲参与论文选题、实验设计和论文修改。

RIGHTS & PERMISSIONS

© Editorial Board of Journal of Jilin University(Medicine Edition). Open access under CC BY-NC-ND license.

Comments

PDF(1335 KB)

Accesses

Citation

Detail

Sections
Recommended

/